论文部分内容阅读
自1952年引用异菸肼以来,已普遍地认为它是一种安全有效的抗结核化学治疗剂。异菸肼和其他抗结核药物合用的大量研究,反复证实其疗效好,并较少副作用。不仅对活动性疾病有效,而且单独使用时对防止静止性感染的发展也有效,故已在美国正式推荐作为一种预防性治疗剂。近20年来,由于广泛运用异菸肼,发现它可能对肝脏有毒性而引起中毒性肝炎。本文作者对华盛顿某一处的职员进行结核病普查,对皮肤结核菌素试验阳性的2321例用异菸肼作预防性治疗,每日一次给予异菸肼300毫克。在治疗达9个月时,有2例因肝炎入院,不久即死亡。一例死
Since isoniazid was quoted in 1952, it has generally been considered as a safe and effective anti-tuberculosis chemotherapeutic agent. Numerous studies of isoniazid and other anti-TB drugs have repeatedly confirmed their efficacy and fewer side effects. It is not only effective for active diseases, but also effective in preventing the development of restless infections when used alone. Therefore, it has been officially recommended as a preventive therapeutic agent in the United States. In the past 20 years, due to the widespread use of isoniazid, it was found that it may be toxic to the liver and cause toxic hepatitis. The authors conducted a census of tuberculosis in staff in a facility in Washington DC. Totally 2321 patients with tuberculin-positive skin test were treated with isoniazid prophylactically and 300 mg of isoniazid were given daily. At 9 months of treatment, 2 were hospitalized for hepatitis and died shortly thereafter. A case of death